Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia.Rhabdomyolysis is a serious but rare side effect of Lamivudine treatment.  Therefore, appropriate biochemical monitoring should be undertaken when it is used in the treatment of hepatitis B. This paper presents a case of Lamivudine-associated rhabdomyolysis in a 31-year-old man with congenital heart disease and hepatitis B. Three days after starting Lamivudine, the patient developed myalgia.  Lamivudine-induced rhabdomyolysis was suspected and the drug was discontinued.  Symptoms and creatine kinase activity improved within four days of Lamivudine cessation and hydration.  Early identification of Lamivudine-induced rhabdomyolysis is key in preventing this potentially fatal drug reaction; withdrawal of Lamivudine may contribute to complete remission of rhabdomyolysis.
Lamivudine
Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia.Rhabdomyolysis is a serious but rare side effect of Lamivudine treatment.  Therefore, appropriate biochemical monitoring should be undertaken when it is used in the treatment of hepatitis B. This paper presents a case of Lamivudine-associated rhabdomyolysis in a 31-year-old man with congenital heart disease and hepatitis B. Three days after starting Lamivudine, the patient developed myalgia.  Lamivudine-induced rhabdomyolysis was suspected and the drug was discontinued.  Symptoms and creatine kinase activity improved within four days of Lamivudine cessation and hydration.  Early identification of Lamivudine-induced rhabdomyolysis is key in preventing this potentially fatal drug reaction; withdrawal of Lamivudine may contribute to complete remission of rhabdomyolysis.
Lamivudine
Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia.Rhabdomyolysis is a serious but rare side effect of Lamivudine treatment.  Therefore, appropriate biochemical monitoring should be undertaken when it is used in the treatment of hepatitis B. This paper presents a case of Lamivudine-associated rhabdomyolysis in a 31-year-old man with congenital heart disease and hepatitis B. Three days after starting Lamivudine, the patient developed myalgia.  Lamivudine-induced rhabdomyolysis was suspected and the drug was discontinued.  Symptoms and creatine kinase activity improved within four days of Lamivudine cessation and hydration.  Early identification of Lamivudine-induced rhabdomyolysis is key in preventing this potentially fatal drug reaction; withdrawal of Lamivudine may contribute to complete remission of rhabdomyolysis.
Lamivudine